Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.

doi:10.1098/rstb.2024.0512

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences - 27 Aug 2026

Simoni-Nieves Arturo, Van Daele Marieke, Konsker Harrison B, Yarden Yosef

Abstract excerpt

The epidermal growth factor receptor (EGFR) plays pivotal role in cancer promotion and progression, particularly in non-small cell lung cancer (NSCLC), where activating EGFR mutations drive tumour growth. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have improved patient survival rates, but resistance inevitably develops through mechanisms ranging from secondary mutations to bypass signalling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutagenesis

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Open in PubMed

Identifiers

PMID: 42656150
DOI: 10.1098/rstb.2024.0512

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.